Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

PI3K/AKT/mTOR Signaling Regulates the Virus/Host Cell Crosstalk in HPV-Positive Cervical Cancer Cells.

Bossler F, Hoppe-Seyler K, Hoppe-Seyler F.

Int J Mol Sci. 2019 May 3;20(9). pii: E2188. doi: 10.3390/ijms20092188. Review.

2.

Membrane partitioning of peptide aggregates: coarse-grained molecular dynamics simulations.

Lien YH, Ram Mahato D, Hoppe-Seyler F, Fischer WB.

J Biomol Struct Dyn. 2019 Feb 27:1-9. doi: 10.1080/07391102.2019.1581660. [Epub ahead of print]

PMID:
30774024
3.

Repression of Human Papillomavirus Oncogene Expression under Hypoxia Is Mediated by PI3K/mTORC2/AKT Signaling.

Bossler F, Kuhn BJ, Günther T, Kraemer SJ, Khalkar P, Adrian S, Lohrey C, Holzer A, Shimobayashi M, Dürst M, Mayer A, Rösl F, Grundhoff A, Krijgsveld J, Hoppe-Seyler K, Hoppe-Seyler F.

MBio. 2019 Feb 12;10(1). pii: e02323-18. doi: 10.1128/mBio.02323-18.

4.

Viral E6/E7 oncogene and cellular hexokinase 2 expression in HPV-positive cancer cell lines.

Hoppe-Seyler K, Honegger A, Bossler F, Sponagel J, Bulkescher J, Lohrey C, Hoppe-Seyler F.

Oncotarget. 2017 Nov 15;8(63):106342-106351. doi: 10.18632/oncotarget.22463. eCollection 2017 Dec 5.

5.

Identification of E6/E7-Dependent MicroRNAs in HPV-Positive Cancer Cells.

Honegger A, Schilling D, Sültmann H, Hoppe-Seyler K, Hoppe-Seyler F.

Methods Mol Biol. 2018;1699:119-134. doi: 10.1007/978-1-4939-7435-1_10.

PMID:
29086374
6.

The HPV E6/E7 Oncogenes: Key Factors for Viral Carcinogenesis and Therapeutic Targets.

Hoppe-Seyler K, Bossler F, Braun JA, Herrmann AL, Hoppe-Seyler F.

Trends Microbiol. 2018 Feb;26(2):158-168. doi: 10.1016/j.tim.2017.07.007. Epub 2017 Aug 17. Review.

PMID:
28823569
7.

Virus/Host Cell Crosstalk in Hypoxic HPV-Positive Cancer Cells.

Hoppe-Seyler K, Mändl J, Adrian S, Kuhn BJ, Hoppe-Seyler F.

Viruses. 2017 Jul 5;9(7). pii: E174. doi: 10.3390/v9070174. Review.

8.

Induction of dormancy in hypoxic human papillomavirus-positive cancer cells.

Hoppe-Seyler K, Bossler F, Lohrey C, Bulkescher J, Rösl F, Jansen L, Mayer A, Vaupel P, Dürst M, Hoppe-Seyler F.

Proc Natl Acad Sci U S A. 2017 Feb 7;114(6):E990-E998. doi: 10.1073/pnas.1615758114. Epub 2017 Jan 23.

9.

Intracellular Analysis of the Interaction between the Human Papillomavirus Type 16 E6 Oncoprotein and Inhibitory Peptides.

Stutz C, Reinz E, Honegger A, Bulkescher J, Schweizer J, Zanier K, Travé G, Lohrey C, Hoppe-Seyler K, Hoppe-Seyler F.

PLoS One. 2015 Jul 7;10(7):e0132339. doi: 10.1371/journal.pone.0132339. eCollection 2015.

10.

Dependence of intracellular and exosomal microRNAs on viral E6/E7 oncogene expression in HPV-positive tumor cells.

Honegger A, Schilling D, Bastian S, Sponagel J, Kuryshev V, Sültmann H, Scheffner M, Hoppe-Seyler K, Hoppe-Seyler F.

PLoS Pathog. 2015 Mar 11;11(3):e1004712. doi: 10.1371/journal.ppat.1004712. eCollection 2015 Mar.

11.

The E6AP binding pocket of the HPV16 E6 oncoprotein provides a docking site for a small inhibitory peptide unrelated to E6AP, indicating druggability of E6.

Zanier K, Stutz C, Kintscher S, Reinz E, Sehr P, Bulkescher J, Hoppe-Seyler K, Travé G, Hoppe-Seyler F.

PLoS One. 2014 Nov 10;9(11):e112514. doi: 10.1371/journal.pone.0112514. eCollection 2014.

12.

Oncogenic human papillomaviruses activate the tumor-associated lens epithelial-derived growth factor (LEDGF) gene.

Leitz J, Reuschenbach M, Lohrey C, Honegger A, Accardi R, Tommasino M, Llano M, von Knebel Doeberitz M, Hoppe-Seyler K, Hoppe-Seyler F.

PLoS Pathog. 2014 Mar 6;10(3):e1003957. doi: 10.1371/journal.ppat.1003957. eCollection 2014 Mar.

13.

Silencing of human papillomavirus (HPV) E6/E7 oncogene expression affects both the contents and the amounts of extracellular microvesicles released from HPV-positive cancer cells.

Honegger A, Leitz J, Bulkescher J, Hoppe-Seyler K, Hoppe-Seyler F.

Int J Cancer. 2013 Oct 1;133(7):1631-42. doi: 10.1002/ijc.28164. Epub 2013 Apr 30.

14.

Endogenous BTG2 expression stimulates migration of bladder cancer cells and correlates with poor clinical prognosis for bladder cancer patients.

Wagener N, Bulkescher J, Macher-Goeppinger S, Karapanagiotou-Schenkel I, Hatiboglu G, Abdel-Rahim M, Abol-Enein H, Ghoneim MA, Bastian PJ, Müller SC, Haferkamp A, Hohenfellner M, Hoppe-Seyler F, Hoppe-Seyler K.

Br J Cancer. 2013 Mar 5;108(4):973-82. doi: 10.1038/bjc.2012.573. Epub 2013 Jan 8.

15.

The inhibitors of nucleotide biosynthesis leflunomide, FK778, and mycophenolic acid activate hepatitis B virus replication in vitro.

Hoppe-Seyler K, Sauer P, Lohrey C, Hoppe-Seyler F.

Hepatology. 2012 Jul;56(1):9-16. doi: 10.1002/hep.25602. Epub 2012 Jun 1.

PMID:
22271223
16.

EZH2 depletion blocks the proliferation of colon cancer cells.

Fussbroich B, Wagener N, Macher-Goeppinger S, Benner A, Fälth M, Sültmann H, Holzer A, Hoppe-Seyler K, Hoppe-Seyler F.

PLoS One. 2011;6(7):e21651. doi: 10.1371/journal.pone.0021651. Epub 2011 Jul 13.

17.

Emerging topics in human tumor virology.

Hoppe-Seyler F, Hoppe-Seyler K.

Int J Cancer. 2011 Sep 15;129(6):1289-99. doi: 10.1002/ijc.26087. Epub 2011 May 5. Review.

18.

Development of peptide aptamer microarrays for detection of HPV16 oncoproteins in cell extracts.

Laurenson S, Pett MR, Hoppe-Seyler K, Denk C, Hoppe-Seyler F, Coleman N, Ko Ferrigno P.

Anal Biochem. 2011 Mar 15;410(2):161-70. doi: 10.1016/j.ab.2010.10.038. Epub 2010 Nov 6.

PMID:
21059336
19.

Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma.

Wagener N, Macher-Goeppinger S, Pritsch M, Hüsing J, Hoppe-Seyler K, Schirmacher P, Pfitzenmaier J, Haferkamp A, Hoppe-Seyler F, Hohenfellner M.

BMC Cancer. 2010 Oct 4;10:524. doi: 10.1186/1471-2407-10-524.

20.

Binding proteins internalized by PTD-fused ligands allow the intracellular sequestration of selected targets by ligand exchange.

Moosmeier MA, Bulkescher J, Hoppe-Seyler K, Hoppe-Seyler F.

Int J Mol Med. 2010 Apr;25(4):557-64.

PMID:
20198304
21.

Targeting Id1 and Id3 by a specific peptide aptamer induces E-box promoter activity, cell cycle arrest, and apoptosis in breast cancer cells.

Mern DS, Hoppe-Seyler K, Hoppe-Seyler F, Hasskarl J, Burwinkel B.

Breast Cancer Res Treat. 2010 Dec;124(3):623-33. doi: 10.1007/s10549-010-0810-6. Epub 2010 Feb 27.

PMID:
20191379
22.

Isolation of peptides blocking the function of anti-apoptotic Livin protein.

Crnković-Mertens I, Bulkescher J, Mensger C, Hoppe-Seyler F, Hoppe-Seyler K.

Cell Mol Life Sci. 2010 Jun;67(11):1895-905. doi: 10.1007/s00018-010-0300-3. Epub 2010 Feb 23.

PMID:
20177953
23.

Transtactin: a universal transmembrane delivery system for Strep-tag II-fused cargos.

Moosmeier MA, Bulkescher J, Reed J, Schnölzer M, Heid H, Hoppe-Seyler K, Hoppe-Seyler F.

J Cell Mol Med. 2010 Jul;14(7):1935-45. doi: 10.1111/j.1582-4934.2009.00846.x. Epub 2009 Jul 7.

24.

Oncogenic human papillomaviruses block expression of the B-cell translocation gene-2 tumor suppressor gene.

Cullmann C, Hoppe-Seyler K, Dymalla S, Lohrey C, Scheffner M, Dürst M, Hoppe-Seyler F.

Int J Cancer. 2009 Nov 1;125(9):2014-20. doi: 10.1002/ijc.24671.

25.

Cellular growth inhibition by FK778 is linked to G1 arrest or S phase accumulation, dependent on the functional status of the retinoblastoma protein.

Hoppe-Seyler K, Weigand K, Lohrey C, Hoppe-Seyler F, Sauer P.

Int J Mol Med. 2009 Mar;23(3):415-20.

PMID:
19212661
26.

A novel peptide motif binding to and blocking the intracellular activity of the human papillomavirus E6 oncoprotein.

Dymalla S, Scheffner M, Weber E, Sehr P, Lohrey C, Hoppe-Seyler F, Hoppe-Seyler K.

J Mol Med (Berl). 2009 Mar;87(3):321-31. doi: 10.1007/s00109-008-0432-1. Epub 2008 Dec 21.

PMID:
19099279
27.

Activation of the enhancer of zeste homologue 2 gene by the human papillomavirus E7 oncoprotein.

Holland D, Hoppe-Seyler K, Schuller B, Lohrey C, Maroldt J, Dürst M, Hoppe-Seyler F.

Cancer Res. 2008 Dec 1;68(23):9964-72. doi: 10.1158/0008-5472.CAN-08-1134. Erratum in: Cancer Res. 2009 Apr 15;69(8):3721.

28.

High nuclear Livin expression is a favourable prognostic indicator in renal cell carcinoma.

Haferkamp A, Bedke J, Vetter C, Pritsch M, Wagener N, Buse S, Crnkovic-Mertens I, Hoppe-Seyler K, Macher-Goeppinger S, Hoppe-Seyler F, Autschbach F, Hohenfellner M.

BJU Int. 2008 Dec;102(11):1700-6. doi: 10.1111/j.1464-410X.2008.07910.x. Epub 2008 Sep 18.

29.

The enhancer of zeste homolog 2 gene contributes to cell proliferation and apoptosis resistance in renal cell carcinoma cells.

Wagener N, Holland D, Bulkescher J, Crnković-Mertens I, Hoppe-Seyler K, Zentgraf H, Pritsch M, Buse S, Pfitzenmaier J, Haferkamp A, Hohenfellner M, Hoppe-Seyler F.

Int J Cancer. 2008 Oct 1;123(7):1545-50. doi: 10.1002/ijc.23683.

30.

Correlation between shiftide activity and HIV-1 integrase inhibition by a peptide selected from a combinatorial library.

Armon-Omer A, Levin A, Hayouka Z, Butz K, Hoppe-Seyler F, Loya S, Hizi A, Friedler A, Loyter A.

J Mol Biol. 2008 Feb 29;376(4):971-82. doi: 10.1016/j.jmb.2007.11.095. Epub 2007 Dec 5.

PMID:
18201721
31.

Expression of inhibitor of apoptosis protein Livin in renal cell carcinoma and non-tumorous adult kidney.

Wagener N, Crnković-Mertens I, Vetter C, Macher-Göppinger S, Bedke J, Gröne EF, Zentgraf H, Pritsch M, Hoppe-Seyler K, Buse S, Haferkamp A, Autschbach F, Hohenfellner M, Hoppe-Seyler F.

Br J Cancer. 2007 Nov 5;97(9):1271-6. Epub 2007 Oct 30.

32.

Identification of cellular targets for the human papillomavirus E6 and E7 oncogenes by RNA interference and transcriptome analyses.

Kuner R, Vogt M, Sultmann H, Buness A, Dymalla S, Bulkescher J, Fellmann M, Butz K, Poustka A, Hoppe-Seyler F.

J Mol Med (Berl). 2007 Nov;85(11):1253-62. Epub 2007 Jun 23.

PMID:
17589817
33.

Targeted inhibition of Livin resensitizes renal cancer cells towards apoptosis.

Crnković-Mertens I, Wagener N, Semzow J, Gröne EF, Haferkamp A, Hohenfellner M, Butz K, Hoppe-Seyler F.

Cell Mol Life Sci. 2007 May;64(9):1137-44.

PMID:
17437058
34.

The anti-apoptotic livin gene is an important determinant for the apoptotic resistance of non-small cell lung cancer cells.

Crnković-Mertens I, Muley T, Meister M, Hartenstein B, Semzow J, Butz K, Hoppe-Seyler F.

Lung Cancer. 2006 Nov;54(2):135-42. Epub 2006 Sep 11.

PMID:
16965834
35.

Peptide aptamer-mediated inhibition of target proteins by sequestration into aggresomes.

Tomai E, Butz K, Lohrey C, von Weizsäcker F, Zentgraf H, Hoppe-Seyler F.

J Biol Chem. 2006 Jul 28;281(30):21345-52. Epub 2006 May 22.

36.

Inhibition of Bax activity is crucial for the antiapoptotic function of the human papillomavirus E6 oncoprotein.

Vogt M, Butz K, Dymalla S, Semzow J, Hoppe-Seyler F.

Oncogene. 2006 Jul 6;25(29):4009-15. Epub 2006 Feb 6.

PMID:
16462759
37.

Isoform-specific silencing of the Livin gene by RNA interference defines Livin beta as key mediator of apoptosis inhibition in HeLa cells.

Crnković-Mertens I, Semzow J, Hoppe-Seyler F, Butz K.

J Mol Med (Berl). 2006 Mar;84(3):232-40. Epub 2005 Dec 31.

PMID:
16437214
38.

Growth suppression induced by downregulation of E6-AP expression in human papillomavirus-positive cancer cell lines depends on p53.

Hengstermann A, D'silva MA, Kuballa P, Butz K, Hoppe-Seyler F, Scheffner M.

J Virol. 2005 Jul;79(14):9296-300.

39.

Peptide aptamers: specific inhibitors of protein function.

Hoppe-Seyler F, Crnkovic-Mertens I, Tomai E, Butz K.

Curr Mol Med. 2004 Aug;4(5):529-38. Review.

PMID:
15267224
41.

Induction of apoptosis in tumor cells by siRNA-mediated silencing of the livin/ML-IAP/KIAP gene.

Crnkovic-Mertens I, Hoppe-Seyler F, Butz K.

Oncogene. 2003 Nov 13;22(51):8330-6.

PMID:
14614456
42.

siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells.

Butz K, Ristriani T, Hengstermann A, Denk C, Scheffner M, Hoppe-Seyler F.

Oncogene. 2003 Sep 4;22(38):5938-45.

PMID:
12955072
43.

Sequence-specific peptide aptamers, interacting with the intracellular domain of the epidermal growth factor receptor, interfere with Stat3 activation and inhibit the growth of tumor cells.

Buerger C, Nagel-Wolfrum K, Kunz C, Wittig I, Butz K, Hoppe-Seyler F, Groner B.

J Biol Chem. 2003 Sep 26;278(39):37610-21. Epub 2003 Jul 2.

44.
45.

Peptide aptamers targeting the hepatitis B virus core protein: a new class of molecules with antiviral activity.

Butz K, Denk C, Fitscher B, Crnkovic-Mertens I, Ullmann A, Schröder CH, Hoppe-Seyler F.

Oncogene. 2001 Oct 4;20(45):6579-86.

46.

Peptide aptamers: new tools to study protein interactions.

Hoppe-Seyler F, Crnkovic-Mertens I, Denk C, Fitscher BA, Klevenz B, Tomai E, Butz K.

J Steroid Biochem Mol Biol. 2001 Aug;78(2):105-11. Review.

PMID:
11566434
47.

Expression pattern of AP-2 transcription factors in cervical cancer cells and analysis of their influence on human papillomavirus oncogene transcription.

Beger M, Butz K, Denk C, Williams T, Hurst HC, Hoppe-Seyler F.

J Mol Med (Berl). 2001 Jun;79(5-6):314-20.

PMID:
11485026
48.

p53 mutations are rare events in recurrent cervical cancer.

Denk C, Butz K, Schneider A, Dürst M, Hoppe-Seyler F.

J Mol Med (Berl). 2001 Jun;79(5-6):283-8.

PMID:
11485021
49.

Peptide aptamers: powerful new tools for molecular medicine.

Hoppe-Seyler F, Butz K.

J Mol Med (Berl). 2000;78(8):426-30. Review.

PMID:
11097111
50.

Induction of apoptosis in human papillomaviruspositive cancer cells by peptide aptamers targeting the viral E6 oncoprotein.

Butz K, Denk C, Ullmann A, Scheffner M, Hoppe-Seyler F.

Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6693-7.

Supplemental Content

Loading ...
Support Center